A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nonalcoholic steatohepatitis (NASH) is a progressive liver disease with no approved treatment. Resmetirom is an oral, liver-directed, thyroid hormone receptor beta-selective agonist in development for the treatment of NASH with liver fibrosis. METHODS: We are conducting an ongoing phase 3 trial involving adults with biopsy-confirmed NASH and a fibrosis stage of F1B, F2, or F3 (stages range from F0 [no fibrosis] to F4 [cirrhosis]). Patients were randomly assigned in a 1:1:1 ratio to receive once-daily resmetirom at a dose of 80 mg or 100 mg or placebo. The two primary end points at week 52 were NASH resolution (including a reduction in the nonalcoholic fatty liver disease [NAFLD] activity score by ≥2 points; scores range from 0 to 8, with higher scores indicating more severe disease) with no worsening of fibrosis, and an improvement (reduction) in fibrosis by at least one stage with no worsening of the NAFLD activity score. RESULTS: Overall, 966 patients formed the primary analysis population (322 in the 80-mg resmetirom group, 323 in the 100-mg resmetirom group, and 321 in the placebo group). NASH resolution with no worsening of fibrosis was achieved in 25.9% of the patients in the 80-mg resmetirom group and 29.9% of those in the 100-mg resmetirom group, as compared with 9.7% of those in the placebo group (P<0.001 for both comparisons with placebo). Fibrosis improvement by at least one stage with no worsening of the NAFLD activity score was achieved in 24.2% of the patients in the 80-mg resmetirom group and 25.9% of those in the 100-mg resmetirom group, as compared with 14.2% of those in the placebo group (P<0.001 for both comparisons with placebo). The change in low-density lipoprotein cholesterol levels from baseline to week 24 was -13.6% in the 80-mg resmetirom group and -16.3% in the 100-mg resmetirom group, as compared with 0.1% in the placebo group (P<0.001 for both comparisons with placebo). Diarrhea and nausea were more frequent with resmetirom than with placebo. The incidence of serious adverse events was similar across trial groups: 10.9% in the 80-mg resmetirom group, 12.7% in the 100-mg resmetirom group, and 11.5% in the placebo group. CONCLUSIONS: Both the 80-mg dose and the 100-mg dose of resmetirom were superior to placebo with respect to NASH resolution and improvement in liver fibrosis by at least one stage. (Funded by Madrigal Pharmaceuticals; MAESTRO-NASH ClinicalTrials.gov number, NCT03900429.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Therefore, incretinbased medications for the treatment of MASLD could be made available, supplementing resmetirom as the only approved medication in the USA and Europe.87”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [87]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Resmetirom is the first compound approved for the treatment of MASH in conjunction with diet and exercise, showing the importance of combining lifestyle changes to pharmacological treatment.91”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [91]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It was not until March 2024 that the U.S. Food and Drug Administration (FDA) approved the first drug, Rezdiffra, for non-alcoholic steatohepatitis (NASH) with liver fibrosis.”
From Mechanisms, efficacy, and future perspectives of cellular-based therapies for liver fibrosis/cirrhosis: focusing on mesenchymal stromal cells (2025) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Resmetirom, a THRβ agonist, showed antisteatogenic potential in a 36-week phase 2 RCT in people with biopsy-confirmed MASH and fibrosis, accompanied by a rise in circulating adiponectin and improved plasma lipid profile [210,211].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [211]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“About 14% of participants in the MAESTRO-NASH trial were on GLP1RA treatment, with stable dosage in the 6 months and stable body weight in the 3 months preceding screening liver biopsy.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [350]
Experimental — accuracy not yet measured
20 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationMach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Self-citationAlberti, K. G. M. M., Zimmet, P., & Shaw, J. (2006) · Diabetic Medicine · doi:10.1111/j.1464-5491.2006.01858.x · Cited by 6,597
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.005 · Cited by 4,945
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000520 · Cited by 3,476
Self-citationAngulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
Self-citationEstes, C., Razavi, H., Loomba, R., Younossi, Z., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29466 · Cited by 2,399
Self-citationMechanisms and disease consequences of nonalcoholic fatty liver disease
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002
Self-citation
Research works printed but not linked: 2
- 24. Conduct of clinical trials of medical products during the COVID-19 public health emergency: guidance for industry, investigators, and institutional review boards. Silver Spring, MD: Food and Drug Administration, August 30, 2021 (https:// www . fda . gov/ media/ 136238/ download/ ). Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the
- 3. ogy/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63: 2935-59.
Cited by
Items 501–600 of 1,003
Liang, S., Lin, M., Wang, J., Wei, H., Huang, S., Yin, T., Xiao, H. P., Shuai, X., & Ren, J. (2025) · Acta Biomaterialia · doi:10.1016/j.actbio.2025.07.010 · Cited by 17
Allahwala, M. A., Marathe, C. S., Nelson, A. J., Psaltis, P. J., & Marathe, J. (2025) · Heart Lung and Circulation · doi:10.1016/j.hlc.2025.07.005 · Cited by 17
Weiskirchen, R. (2025) · Exploration of Drug Science · doi:10.37349/eds.2025.1008132 · Cited by 10
Chen, J., Wu, X., Chen, T., Cui, T., Wu, D., Qiu, M., Yi, Q., Zhang, Z., Ma, C., Gao, Y., et al. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157552 · Cited by 10
Targeting THR-β for MASLD Treatment: Current Progression and Emerging Prospects
Li, J., Chen, R., Zhang, J., He, J., Wang, Y., & Li, Y. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03114 · Cited by 11
Genetic Predisposition to MASLD: Potential for Therapeutic Management
Karapanagiotidi, F., Boutari, C., & Sinakos, E. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27041933 · Cited by 10
“In March 2024, resmetirom, a THR β selective agonist, received accelerated approval from the FDA for the treatment of MASH in patients with moderate to advanced liver fibrosis (F2–F3), based on the findings of the phase III MAESTRO-NASH clinical trial [38].”
Zhang, J., Sun, Y., Yu, M., Hu, Y., Huang, X., Yang, G., Zhang, R., & Ge, M. (2024) · Biological Trace Element Research · doi:10.1007/s12011-024-04294-2 · Cited by 10
“The above results are consistent with the pathological changes in the occurrence of liver fibrosis [23, 24].”
Zhang, J., Li, Y., Liu, Y., Ma, N., Qian, S., Chen, Y., Duan, Y., Xiang, X., & He, Y. (2024) · Cell & Bioscience · doi:10.1186/s13578-024-01267-9 · Cited by 11
“Moreover, Recently, an ongoing phase 3 trial of a large enrolled population has consolidated the evidence that Resmetirom is superior to placebo in improving MASH outcome [102].”
BackgroundWu, D., & van de Graaf, S. F. J. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116437 · Cited by 13
Thyroid Hormone Receptors in Control of Heart Rate
Dore, R., & Mittag, J. (2024) · Endocrinology · doi:10.1210/endocr/bqae093 · Cited by 13
Righetti, R., Cinque, F., Volpe, M. T., & Sebastiani, G. (2024) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2024.2385487 · Cited by 13
“Resmetirom is currently being evaluated in several randomized controlled trials [67,71–73], and its efficacy has been assessed in a recent phase 3 trial, MAESTRO-NASH [67], demonstrating fibrosis improvement in patients with F2-F3 fibrosis.”
Yanagisawa, H., Maeda, H., Noguchi, I., Tanaka, M., Wada, N., Nagasaki, T., Kobayashi, K., Kanazawa, G., Taguchi, K., Chuang, V. T. G., et al. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103314 · Cited by 10
Detecting altered hepatic lipid oxidation by MRI in an animal model of MASLD
McLeod, M., Chang, M. C., Rushin, A., Ragavan, M., Mahar, R., Sharma, G. K., Badar, A., Giacalone, A., Glanz, M. E., Malut, V. R., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101714 · Cited by 12
Song, G. Y., Kim, S. M., Back, S. H., Yang, S.-B., & Yang, Y. M. (2024) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2024.083 · Cited by 13
Kim, J., Ito, T., Arai, T., Atsukawa, M., Kawanaka, M., Toyoda, H., Honda, T., Yu, M., Yoon, E. L., Jun, D. W., et al. (2024) · Diagnostics · doi:10.3390/diagnostics14222500 · Cited by 14
Aguado, D. M., Sierra, J. M. C., Villalba, A., Siddiqi, H., VALLEJO-VIGO, R. M., Lara‐Romero, C., Martín-Fernández, M., Fernández-Patón, M., Alfaro‐Cervelló, C., Crespo, A., et al. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.10.014 · Cited by 15
Self-citationPreventing the progression of cirrhosis to decompensation and death
Villanueva, C., Tripathi, D., & Bosch, J. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-01031-x · Cited by 40
“accelerates ACLD progression 34 .”
Theofilis, P., Oikonomou, E. K., Karakasis, P., Pamporis, K., Dimitriadis, K. S., Kokkou, E., Lambadiari, V., Siasos, G., Tsioufis, K. P., & Tousoulis, D. (2025) · Liver International · doi:10.1111/liv.70016 · Cited by 10
The transcription factor ZNF469 regulates collagen production in liver fibrosis
Steinhauser, S., Estoppey, D., Buehler, D. P., Xiong, Y., Pizzato, N., Rietsch, A., Wu, F., Leroy, N., Wunderlin, T., Claerr, I., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.182232 · Cited by 17
“Despite the concerning epidemiologic trends for MASLD, only one drug therapy has been recently approved for metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced fibrosis (3, 4).”
The prognostic role of Fibrosis-4 score in heart failure with reduced ejection fraction
Mohamed, A. A., Christensen, D. M., Mohammad, M., Gluud, L. L., Knop, F. K., Biering‐Sørensen, T., Torp-Pedersen, C., Andersson, C., Schou, M., & Gislason, G. H. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133174 · Cited by 11
Modeling hepatic steatosis with human adult stem cell-derived liver organoids
Zhu, L., Liu, S., Wang, Z., Yang, Y., Han, P., Tong, W., Zhao, T., Wang, L., Cui, T., Yang, L., et al. (2025) · iScience · doi:10.1016/j.isci.2025.112344 · Cited by 13
Targeting PKLR in liver diseases
Yuan, M., Shi, M., Yang, H., Ashraf, S., Iqbal, S., Türkez, H., Borén, J., Zhang, C., Uhlén, M., Altay, Ö., et al. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.03.009 · Cited by 12
Muñoz‐Espinosa, L. E., Torre, A., Cisneros, L., Montalvo, I., Malé, R., Mejía, S., Aguilar, J. R., Lizardi, J., Zuñiga‐Noriega, J., Eugenia Icaza, M., et al. (2025) · Liver International · doi:10.1111/liv.70131 · Cited by 10
Incretins and MASLD: at the Crossroads of Endocrine and Hepatic Disorders
Farrugia, M. A., Pini, E., Tran, A., Chevalier, N., Anty, R., & Gual, P. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00646-8 · Cited by 13
“Harrison et al. demonstrated the resolution of MASH without worsening fibrosis, and improvement in liver fibrosis without worsening MASH compared with placebo [104].”
FGF21 Analogues and MASLD: A Summary of Preclinical and Clinical Data
Boutari, C., Triantafyllou, A., Papalavrentios, L., Goulis, I., & Sinakos, E. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128374854250709050425 · Cited by 12
Resmetirom for MASH-related cirrhosis
Feng, G., Hernández–Gea, V., & Zheng, M. (2024) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(24)00124-9 · Cited by 10
Fujiwara, A., Takemura, K., Tanaka, A., Matsumoto, M., Katsuyama, M., Okanoue, T., Yamaguchi, K., Itoh, Y., Iwata, K., Amagase, K., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-70296-8 · Cited by 9
Zhi, Y., Dong, Y., Li, X., Zhong, W., Lei, X., Tang, J. T., & Mao, Y. (2024) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3846 · Cited by 10
“…analysis of 996 patients from MAESTRO‐MASH revealed that 100 mg resmetirom achieved a 29.9% response rate in MASH resolution and a 25.9% reduction in fibrosis, which was significantly higher than that in the placebo group, while also demonstrating the ability to lower low‐density lipoprotein [27].”
InfluentialH3K9me3 demethylation by JMJD2B is regulated by pirfenidone resulting in improved NASH
Rodríguez-Sanabria, J. S., Rosas-Campos, R., Vázquez-Esqueda, Á. O., Palacios‐Marin, I., Jiménez‐Chillarón, J. C., Escutia-Gutiérrez, R., Jave‐Suárez, L. F., Galicia‐Moreno, M., Monroy-Ramírez, H. C., Reyes, E. C., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-75458-2 · Cited by 11
Abbasi, L., Irfan, Q., Zaidi, S. M. M., Jawed, I., Malik, A., & Kaleem, S. (2024) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002901 · Cited by 11
Zou, X., & Brigstock, D. R. (2024) · Biomedicines · doi:10.3390/biomedicines12122848 · Cited by 10
Cazac, G.-D., Lăcătușu, C.-M., Grigorescu, E.-D., Foșălău, A.-B., Onofriescu, A., & Mihai, B. M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041042 · Cited by 10
“This agent has shown histological efficacy in addressing steatohepatitis and fibrosis, together with a favorable safety and tolerability profile [4,29].”
Wang, Y., Chen, Z., Wei, B., Zhang, R., Zhang, X., & Xu, W. (2025) · Scientific Reports · doi:10.1038/s41598-025-90667-z · Cited by 10
“…ablation, incorporating newly discovered medications such as oral, liver-directed, thyroid hormone receptor beta–selective agonist resmetirom 40 , Fibroblast growth factor 21 (FGF21) analogue pegozafermin 41 , novel agonists of glucagon-like peptide-1 receptors 42,43 , or lifestyle…”
John, K., Franck, M., Geier, A., Schattenberg, J. M., Schulze-Osthoff, K., Bantel, H., Demir, M., Rau, M., Sowa, J.-P., & Wedemeyer, H. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.02.014 · Cited by 10
Self-citationSingle-cell landscape of peripheral immune cells in MASLD/MASH
Steixner-Kumar, A. A., Santacruz, D., Geiger, T., Rust, W., Böttner, D., Krenkel, O., Bahrami, E., Okafo, G., Barth, T. F. E., Haenle, M. M., et al. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000643 · Cited by 20
“[4] Although the molecular understanding of immunological processes for MASLD/MASH is growing (for a review, see the study by Huby et al [5 – 7] ), little is known about the peripheral immune landscape of these patients.”
Li, G., Wong, V. W., Chan, R., Sin, D. M.-C., Chu, C. W., Wong, V., Cheung, C., Lam, S., Lin, H., Yeung, S. S. Y., et al. (2025) · The Lancet HIV · doi:10.1016/s2352-3018(25)00032-3 · Cited by 10
Metabolic-immune microenvironment crosstalk mediating ICI resistance in MASH-HCC
Ju, Y., Xu, K., Chen, X., Wu, T., & Yuan, Y. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.06.008 · Cited by 17
Proteomic signatures reflect effects of semaglutide treatment for MASH
Schattenberg, J. M., Grønbæk, H., Kliers, I., Ladelund, S., Long, M. T., Nygård, S. B., Sanyal, A. J., & Davies, M. J. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101521 · Cited by 14
Self-citationRahman, A. T., Choi, J., Kyung, W., Kang, S., Lee, S., & Jon, S. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123576 · Cited by 11
Jamal, F., Elshaer, A., Odeh, N. B., Alatout, M. H., Shahin, T., Worden, A. R., Albunni, H. N., Lizaola‐Mayo, B., Jayasekera, C. R., Chascsa, D. M. H., et al. (2025) · Life · doi:10.3390/life15081306 · Cited by 14
“Following this, the American Association for the Study of Liver Diseases (AASLD) updated its clinical guidance to incorporate resmetirom, stressing the importance of continued real-world data collection and long-term studies to define better its role in managing MASLD and MASH [30].”
Younossi, Z. M., Wong, V. W., Tsochatzis, E. A., Castéra, L., Betel, M., Henry, L. L., & Zelber‐Sagi, S. (2025) · Liver International · doi:10.1111/liv.70311 · Cited by 14
“The approval of resmetirom and semaglutide for MASH, and the use of GLP-1 receptor agonists for weight loss and glycae-mic control, represent significant milestones in MASLD/MASH treatment [84, 86].”
InfluentialSelf-citationDas, S., Agarwal, K., Kapoor, N., Lakhani, O., & Gupta, A. D. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000935 · Cited by 9
Metabolic dysfunction-associated steatotic liver disease
Hsu, C., & Alazawi, W. (2025) · Clinical Medicine · doi:10.1016/j.clinme.2025.100526 · Cited by 14
Bianco, A., Bonfiglio, C., Franco, I., Bagnato, C. B., Verrelli, N., Stabile, D., & Shahini, E. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14217553 · Cited by 9
Liu, J., Yang, F., Gao, B., Yang, L., Cao, Y., & Zhou, Y. (2025) · Archives of Pharmacal Research · doi:10.1007/s12272-025-01574-w · Cited by 15
Youhanna, S., Taebnia, N., Liang, Y., Cheng, N., Wang, Y., Michel, M., & Lauschke, V. M. (2025) · Advanced Biology · doi:10.1002/adbi.202500337 · Cited by 9
Yang, F., Wang, W., Qiu, F., Qing, R., Gao, Q., Yan, X., Wu, D., Hui, H., Dang, R., Jiang, G., et al. (2026) · Nature Metabolism · doi:10.1038/s42255-025-01436-1 · Cited by 9
Current Drug Development Pipeline for MASLD and MASH: Focusing on Cardiovascular Comorbidities
Александровна, П. В., & Okovityi, S. V. (2026) · Biomedicines · doi:10.3390/biomedicines14040909 · Cited by 10
Metabolic drivers of MASLD and MASH: from hormonal imbalance to fibrosis
Gastaldelli, A., Scoditti, E., & Macedo, M. P. (2026) · Diabetologia · doi:10.1007/s00125-026-06774-7 · Cited by 12
“The positive results of the MAESTRO trial [117] have led to the regulatory approval of resmetirom, a THR-β agonist, as the first targeted antifibrotic therapy for MASH.”
APASL clinical practice guidelines on the management of chronic hepatitis B infection: a 2026 update
You, H., Maiwall, R., Chen, J., Ahn, S. H., Dokmeci, K., 窦晓光, El-Sayed, M., Fan, J.-G., Gani, R., Gao, Z., et al. (2026) · Hepatology International · doi:10.1007/s12072-026-11108-1 · Cited by 21
Use of PNPLA3, TM6SF2, and HSD17B13 for detection of fibrosis in MASLD in the general population
Rashu, E. B., Werge, M. P., Hetland, L. E., Thing, M., Nabilou, P., Kimer, N., Junker, A. E., Jensen, A.-S. H., Nordestgaard, B. G., Stender, S., et al. (2024) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2024.102389 · Cited by 12
Alfieri, C., Molinari, P., Cinque, F., Vettoretti, S., Cespiati, A., Bignamini, D., Nardelli, L., Fracanzani, A. L., Castellano, G., & Lombardi, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147728 · Cited by 13
“Only Resmetirom, an agonist of the thyroid hormone receptors, has been recently approved by the Food and Drug Administration for the treatment of MASLD; however, it is not widely available worldwide [72].”
BackgroundHashim, H. T., Alhatemi, A. Q. M., Riaz, S., Al-Ghuraibawi, M. A., Alabide, A. S., Saeed, H., Sulaiman, F. A., Alhussain, M. A. A., Shallan, M. A., Al‐Obaidi, A. D., et al. (2024) · JGH Open · doi:10.1002/jgh3.70025 · Cited by 13
The LIDPAD Mouse Model Captures the Multisystem Interactions and Extrahepatic Complications in MASLD
Low, Z. S., Chua, D., Cheng, H. S., Tee, R., Tan, W., Ball, C., Sahib, N. B. E., Ng, S. S., Qu, J. T., Liu, Y., et al. (2024) · Advanced Science · doi:10.1002/advs.202404326 · Cited by 11
Borozan, S., Vujošević, S., Mikhailidis, D. P., & Muzurović, E. M. (2024) · Current Vascular Pharmacology · doi:10.2174/0115701611340703240809044916 · Cited by 10
Vidal‐Cevallos, P., & Chávez-Tapia, N. C. (2024) · Med · doi:10.1016/j.medj.2024.03.013 · Cited by 12
Karnawat, K., Parthasarathy, R., Sakhrie, M., Karthik, H., Krishna, K. V., & Balachander, G. M. (2024) · Journal of Materials Chemistry B · doi:10.1039/d4tb00738g · Cited by 8
Khatoon, S., Das, N., Chattopadhyay, S., Joharapurkar, A. A., Singh, A., Patel, V. J., Nirwan, A., Kumar, A., Mugale, M. N., Mishra, D. P., et al. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176800 · Cited by 8
Glucagon-Like Peptide 1 Receptor Agonists for Obesity: Efficacy, Side Effects, and Risks
Thota-Kammili, S., Tama, E., & Andrade, M. D. H. (2024) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-024-00452-6 · Cited by 10
“Currently, there is only one medication, resmetirom—a TSH receptor selective agonist, that has recently received approval for treatment of MASH and MASLD [28].”
Lonardo, A., & Weiskirchen, R. (2024) · Metabolites · doi:10.3390/metabo14080408 · Cited by 9
“Promising data on the efficacy of resmetirom, a selective agonist of thyroid hormone receptor-β , provides additional (though indirect) evidence of the role of the thyroid hormone in the development and progression of MASLD [29].”
BackgroundLiu, S., Jiang, X., Fu, J., Wong, V. W., Zhong, V. W., & Qi, X. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.07.005 · Cited by 11
Flavin, B. M. (2024) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2024.30.9-a.s1 · Cited by 14
Chen, S., Zeng, Q., Cai, X., Xue, J., Yin, G., Song, P., Tang, L., Klein, C., Tacke, F., Guillot, A., et al. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.98362 · Cited by 8
Biomarker Discovery in Liver Disease Using Untargeted Metabolomics in Plasma and Saliva
Daniels, N. J., Hershberger, C. E., Kerosky, M., Wehrle, C. J., Raj, R., Aykun, N., Allende, D. S., Aucejo, F., & Rotroff, D. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251810144 · Cited by 9
“In addition to weight loss, Resmetirom has been FDA-approved for treatment of NASH without cirrhosis [13].”
BackgroundVenhorst, J., Hanemaaijer, R., Dulos, R., Caspers, M. P. M., Toet, K. H., Attema, J., de Ruiter, C., Kalkman, G. J., Rankouhi, T. R., de Jong, J. C. B. C., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1442752 · Cited by 8
Chen, M., Zong, J., He, F., Zhou, W., Liu, R., Xia, H., Mao, M., Jin, C., Wang, K., & Ding, K. (2024) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2024.122860 · Cited by 12
Nikoli, A., Orfanidou, M., Goulas, A., Goulis, D. G., & Pοlyzos, S. A. (2024) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16768 · Cited by 10
From MASLD to PAD: Looking for Cardiovascular Disease Starting from Metabolic Status
Boccatonda, A., D’Ardes, D., Moronti, V., Santilli, J., Cipollone, A., Lessiani, G., Gregorio, N. D., Serra, C., Piscaglia, F., Ferri, C., et al. (2024) · Medicina · doi:10.3390/medicina60111781 · Cited by 10
Thyroid hormones are required for thermogenesis of beige adipocytes induced by Zfp423 inactivation
Roth, L. G., Hoffmann, A., Hagemann, T., Wagner, L., Strehlau, C., Sheikh, B. N., Donndorf, L., Ghosh, A., Noé, F., Wolfrum, C., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114987 · Cited by 8
Aberrant basement membrane production by HSCs in MASLD is attenuated by the bile acid analog INT-767
Ramachandran, P., Brice, M., Sutherland, E. F., Hoy, A. M., Papachristoforou, E., Li, J., Turner, F. S., Kendall, T. J., Marwick, J. A., Carragher, N. O., et al. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000574 · Cited by 9
FDA’s approval of resmetirom (Rezdiffra): a breakthrough in MASH management
Azam, M. M., Mukhtar, S., Haris, M., Laique, F., Amir, S., Mohiuddin, M., & Giri, B. (2024) · Exploration of Drug Science · doi:10.37349/eds.2024.00078 · Cited by 12
Wang, R., Chen, Y., Han, J., Ye, H., Yang, H., Li, Q., He, Y., Ma, B., Zhang, J., Ge, Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-55295-7 · Cited by 10
Velji-Ibrahim, J., Woodard, J. S., Alden, J., & Abrams, G. A. (2025) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000002132 · Cited by 11
Lam, B. P., Bartholomew, J., Bau, S., Gilles, H., Keller, A., Moore, A., Nader, K., Richards, L., Henry, L. L., & Younossi, Z. M. (2025) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000002140 · Cited by 9
Self-citationRyu, T., Chang, Y. W., Yoo, J., Lee, S. H., Jeong, S. W., Kim, S. G., Kim, Y. S., Kim, H. S., Yang, K., & Jang, J. Y. (2025) · Clinical Nutrition · doi:10.1016/j.clnu.2025.02.012 · Cited by 8
Kovynev, A., Charchuta, M. M., Begtašević, A., Ducarmon, Q. R., Rensen, P. C. N., & Schönke, M. (2025) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00317.2024 · Cited by 9
Luongo, C., Girolamo, D. D., Ambrosio, R., Cintio, S. D., Stefano, M. A. D., Porcelli, T., & Salvatore, D. (2025) · Endocrinology · doi:10.1210/endocr/bqaf050 · Cited by 9
“In this scenario, the recent approval of resmetirom, a selective THR-β agonist, for the treatment of nonalcoholic steatohepatitis is an example of how we can benefit from manipulating TH signaling specifically in some tissues without exposing patients to systemic dysthyroidism (35).”
Chen, R. K., Petrazzini, B. O., Duffy, Á., Rocheleau, G., Jordan, D. M., Bansal, M. B., & Do, R. (2025) · Genome biology · doi:10.1186/s13059-025-03518-5 · Cited by 11
“This is crucial given that the FDA has only approved one drug for the treatment of MASLD [4].”
Self-citationPennisi, G., Maria, G. D., Enea, M., Vaccaro, M., Celsa, C., Antonucci, M., Ciancimino, G., Ciccioli, C., Infantino, G., Mantia, C. L., et al. (2025) · Liver International · doi:10.1111/liv.70056 · Cited by 11
“The clinical trial conducted by Harrison et al. [5], known as MAESTRO-NASH, reached Phase 3.”
InfluentialUnderrepresentation of Asians in diagnostic test development and drug trials in MASLD
Mak, L., Yip, T. C., Lee, C., Lai, J. C., & Wong, V. W. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.03.005 · Cited by 9
Change in cT1 Following Interventions in MASLD: A Systematic Review and Meta-Analysis
Andersson, A., Loomba, R. S., Beyer, C., Mouchti, S., Vuppalanchi, R., Harisinghani, M. G., Ajaz, S., Dinani, A. M., Banerjee, A., Muthiah, M. D., et al. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.03.003 · Cited by 13
Self-citationBalakrishnan, J., Desouza, C. V., Thakare, R., Alnouti, Y., & Saraswathi, V. (2025) · Journal of Lipid Research · doi:10.1016/j.jlr.2025.100823 · Cited by 8
Messer, E. K., Petroff, D., Schattenberg, J. M., Zeuzem, S., von der Ohe, M., Ludwig, L., Demir, M., Buggisch, P., Stein, K., Serfert, Y., et al. (2025) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2592-6109 · Cited by 11
“…on cardiometabolic risk factors, because in the resmetirom phase III registrational study at least three of five cardiometabolic risk factors according to a modified version of the International Diabetes Foundation criteria for metabolic syndrome had to be present in eligible patients [10, 26].”
InfluentialSelf-citationThe Immune Microenvironment: New Therapeutic Implications in Organ Fibrosis
Chen, X., Wu, C. F., Tang, F., Zhou, J., Mo, L., Li, Y., & He, J. (2025) · Advanced Science · doi:10.1002/advs.202505067 · Cited by 15
Metabolic dysfunction-associated steatotic liver disease in people with HIV
Gattu, A. K., & Fourman, L. T. (2025) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000952 · Cited by 11
Zhong, H., Liu, C., Huang, Z., Tan, P., Chen, H., & Fu, W. (2025) · American Journal Of Pathology · doi:10.1016/j.ajpath.2025.02.003 · Cited by 10
Tamir, T. Y., Chaudhary, S., Li, A. X., Trojan, S., Flower, C. T., Vo, P., Cui, Y., Davis, J. C., Mukkamala, R. S., Venditti, F. N., et al. (2024) · Molecular Cell · doi:10.1016/j.molcel.2025.05.007 · Cited by 8
Shu, R., Tian, S., Qu, W., Yang, J., Shi, W., Li, X., Zou, T., Jiang, C., Zhang, Y., Yang, Z., et al. (2025) · Journal of Lipid Research · doi:10.1016/j.jlr.2025.100835 · Cited by 8
“Hitherto, only resmetirom has been approved for MASH therapy that should be accompanied by exercise and dietary change, with a resolving rate limited to less than 30% (7).”
Hu, S., Liang, X., Qin, Y., Li, Y., Liu, Y., Liu, C., Lin, Z.-X., Geng, C., Xu, Y., Wei, D., et al. (2025) · Advanced Science · doi:10.1002/advs.202411984 · Cited by 12
Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs): A Pan-Steatotic Liver Disease Treatment?
Chrysavgis, L., Mourelatou, N. G., & Cholongitas, Ε. (2025) · Biomedicines · doi:10.3390/biomedicines13071516 · Cited by 10
“Resmetirom, an orally active, selective THR-β agonist has recently became the first FDA-approved medication for MASH since it improved liver inflammation and fibrosis, meeting the primary endpoints [115].”
Hashim, M. M. A., Khan, M. A. M., Ashraf, M. U., Mohsin, S., Zahoor, K., Niazi, J., Khan, A., Muzaffar, S., Makhdumi, M., Ibad, O. A., et al. (2025) · Cureus · doi:10.7759/cureus.86963 · Cited by 19
“The pathological progression of NAFLD, recently redefined as MASLD, represents a dynamic and multifactorial continuum driven by metabolic stress, systemic inflammation, genetic susceptibility, and environmental influences [13].”
InfluentialSteatotic Liver Disease in Older Adults: Clinical Implications and Unmet Needs
Clayton‐Chubb, D., Kemp, W. W., Majeed, A., Lange, P. W., Fitzpatrick, J. A., Vaz, K., Lubel, J. S., Hodge, A. D., Ryan, J. L., McNeil, J. J., et al. (2025) · Nutrients · doi:10.3390/nu17132189 · Cited by 14
“Taken together, these actions improve lipid metabolism, mitochondrial β -oxidation, reduce VLDL and triglycerides, and reduce liver stiffness and fat content, all with relatively minor deleterious impacts on other tissues, such as the heart and bone density [261–263].”
Heidenreich, J. F., Tang, J., Tamada, D., Müller, L., Grunz, J., Souza, R. D. V., Anagnostopoulos, A. A., Pirasteh, A., Reeder, S. B., & Hernando, D. (2025) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.70033 · Cited by 8
“Hence, there is an emerging clinical need for non-invasive liver fat quantification to enable early detection, risk stratification, and disease monitoring [2] or treatment assessment of recently approved treatments for MASLD [5, 6].”
Wang, Y., Zhao, Y., Zhao, W., Chen, H., Cao, Z., Li, H., Tang, Y., Zhu, X., & Yao, P. (2025) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2025.08.018 · Cited by 9
Nutrients as epigenetic modulators in metabolic dysfunction-associated steatotic liver disease
Rodríguez, S., Dahlem, M. L. F., Rossoni, C., Marroni, N. P., Marroni, C. A., & Fernandes, S. A. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i8.108182 · Cited by 8
Genomic medicine in hepatology: mechanisms and liver treatment strategies
Kozlov, D., Rodimova, S. A., Filatov, P. V., Mozherov, A. M., Timashev, P. S., Zyuzin, M. V., & Kuznetsova, D. S. (2025) · Molecular Medicine · doi:10.1186/s10020-025-01358-4 · Cited by 11
“For example, the recently approved drug resmetirom provided improvement in fibrosis in only 24–26% of study participants[548], while another study reported high rates of drug discontinuation due to adverse events and the need for long-term follow-up in patients taking res-metir [549].”
Neff, G. W. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70148 · Cited by 13
Self-citationConsiderations in the Diagnoses and Management of Hepatic Disease in Older Adults
Brown, C. L., & Bajaj, J. S. (2025) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003641.07 · Cited by 10
The complexity of the relationship between thyroid disease and body weight
Jonklaas, J. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01190-0 · Cited by 10
Management of patients with type 2 diabetes and MASLD: An overview and joint statement
Chouik, Y., Canivet, C. M., Julla, J., Mouillot, T., Parlati, L., Rouland, A., Smati, S., Tramunt, B., Anty, R., Boursier, J., et al. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101709 · Cited by 12
Metadata
- Authors
- Harrison, S. A., Bedossa, P., Guy, C. D., Schattenberg, J. M., Loomba, R., Taub, R., Labriola, D., Moussa, S. E., Neff, G. W., Rinella, M. E., Anstee, Q. M., Abdelmalek, M. F., Younossi, Z., Baum, S. J., Francque, S., Charlton, M. R., Newsome, P. N., Lanthier, N., Schiefke, I., Mangia, A., Pericàs, J. M., Patil, R., Sanyal, A. J., Noureddin, M., Bansal, M. B., Alkhouri, N., Castera, L., Rudraraju, M., & Ratziu, V.
- Affiliations
- University Hospitals Birmingham NHS Foundation Trust (GB)
- From the University of Oxford, Oxford (S.A.H.), the Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne (Q.M.A.), and the National Institute for Health Research, Biomedical Research Centre at University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham, Birmingham (P.N.N.) — all in the United Kingdom; Pinnacle Clinical Research, San Antonio (S.A.H., M.R.), South Texas Research Institute, Edinburg (R.P.), and Houston Methodist Hospital, Houston Research Institute, Houston (M.N.) — all in Texas; Liverpat and University of Paris (P.B.), INSERM, Unité Mixte de Recherche Scientifique (UMRS) 1139, Centre de Recherche sur l’Inflammation (L.C.), and Sorbonne Université, ICAN Institute for Cardiometabolism and Nutrition, Assistance Publique–Hôpitaux de Paris (APHP), INSERM, UMRS 1138, Centre de Recherche des Cordeliers (V.R.), Paris, and Université Paris-Cité, Department of Hepatology, Beaujon Hospital, APHP, Clichy (L.C.) — ...
- Universitat Autònoma de Barcelona (ES)
- Houston Methodist (US)
- ORCID
- Harrison, Stephen A.
- Guy, Cynthia D.
- Schattenberg, Jörn M.
- Loomba, Rohit
- Taub, Rebecca
- Neff, Guy W.
- Rinella, Mary E.
- Anstee, Quentin M.
- Abdelmalek, Manal F.
- Younossi, Zobair
- Baum, Seth J.
- Francque, Sven
- Charlton, Michael R.
- Newsome, Philip N.
- Lanthier, Nicolas
- Mangia, Alessandra
- Pericàs, Juan M.
- Patil, Rashmee
- Sanyal, Arun J.
- Noureddin, Mazen
- Bansal, Meena B.
- Alkhouri, Naim
- Rudraraju, Madhavi
- Ratziu, Vlad
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-02-08
- Volume
- 390
- Issue
- 6
- Pages
- 497-509
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4391592880
- Cited by
- 2,084
- References
- 26
- Citations by year
- 2026: 797 · 2025: 807 · 2024: 478
- FWCI
- 635.31
- Type
- journal article
- Language
- en
- Open access
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (publishedVersion, other-oa)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, other-oa)
- HAL (submittedVersion)
- Digital Access to Libraries (submittedVersion, other-oa)
- Digital Access to Libraries (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Open Access CRIS of the University of Bern
- Funders
- Madrigal Pharmaceuticals
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- resmetirom, nonalcoholic steatohepatitis, liver fibrosis, thyroid hormone receptor beta agonist, NASH resolution, fibrosis regression, NAFLD activity score, LDL cholesterol, triglycerides, cirrhosis prevention, drug safety and tolerability
- MeSH terms
- Adult, Biopsy, Dose-Response Relationship, Drug, Double-Blind Method, Humans, Liver, Liver Cirrhosis, Pyridazines, Uracil, Treatment Outcome, Thyroid Hormone Receptors beta, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.